Drug Interactions in Dentistry: A Patient's Guide

The patient walks in. Sits down. You ask what medications they take. “Nothing special, doc — one for blood pressure, one for the blood, one to sleep.” Three pills, three potential interactions with what you’re about to do.

This article is a map. Not a generic interaction checker — those don’t know you’re about to inject epinephrine into vascularized tissue, or that you need to prescribe ibuprofen to someone already on warfarin. Here we’re talking about the interactions that matter in the dental chair, with the evidence behind them.

Anticoagulants: the unjustified fear

Warfarin (Coumadin) was dentistry’s bogeyman for decades. Generations of dentists refused extractions or demanded drug holidays “just to be safe.” The data say otherwise.

A prospective study of 216 patients (Johansson et al., 2025) measured post-extraction bleeding without interrupting either DOACs or warfarin. Result: clinically relevant bleeding — the kind requiring reintervention — occurred in 3% of DOAC patients and 11% of those on warfarin. No major hemorrhage. No hospitalization. No transfusion.

The meta-analysis by Hua et al. (2021), covering 8 studies and over 1,100 patients, confirms: DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) carry equal or lower post-extraction bleeding risk compared to warfarin (RR 0.68; 95% CI 0.49–0.95).

And Ono et al.’s Japanese cohort (2022) — 5,253 patients — found overlapping incidences: 2.2% in the warfarin group, 1.9% in the DOAC group.

The message is the same across all three studies: do not stop the anticoagulant. The thromboembolic risk from discontinuation far outweighs a post-extraction bleed controllable with gelatin sponge and tranexamic acid. Lu et al. (2018), studying 1,331 Taiwanese patients, put numbers on it: with INR <4.0, you extract without touching the medication.

Antiplatelets: aspirin and clopidogrel stay

Same logic as anticoagulants, but the numbers are even more reassuring. Dinkova et al. (2017) extracted teeth in 130 patients on aspirin or clopidogrel — half continuing the drug, half stopping it 72 hours prior. Difference in bleeding? None that reached statistical significance. No major hemorrhage in either group.

Schreuder and Peacock (2015), writing in JADA, summarize the principle: the bleeding risk for an extraction under single or dual antiplatelet therapy is lower than the thromboembolic risk from discontinuation. Local hemostasis — resorbable sponge, compression, suturing, possibly tranexamic acid — suffices in nearly all cases.

One caveat: dual antiplatelet therapy (aspirin + clopidogrel), typical after coronary stenting, warrants more caution. Lu et al. (2018) report a 4.2% bleeding incidence on dual therapy, versus 1.1% on aspirin alone. Manageable, but worth planning for.

Beta-blockers and epinephrine: a real interaction

This one is the least known to patients and the most underestimated by dentists. Hersh and Giannakopoulos (2010) describe it clearly: non-selective beta-blockers — propranolol, nadolol, timolol — can amplify the pressor effect of the epinephrine in local anesthetic.

The mechanism: epinephrine stimulates both alpha receptors (vasoconstriction → pressure up) and beta-2 receptors (vasodilation → pressure down). Non-selective beta-blockers shut down the beta-2 pathway, leaving alpha-mediated vasoconstriction unopposed. Result: hypertensive spike with reflex bradycardia.

With 1-2 cartridges of lidocaine with 1:100,000 epinephrine, the reaction is usually modest. But Hersh reports a case where a single individual had an exaggerated response — individual hypersensitivity that no protocol predicts. Accidental intravascular injection amplifies everything.

What to do:

• Know if the patient takes a non-selective beta-blocker — not everyone volunteers this.
• Limit epinephrine (maximum 2 cartridges with 1:100,000).
• Aspirate before injecting — always, but here more than ever.
• If a vasoconstrictor-free anesthetic is needed, 3% mepivacaine is the alternative.

Selective beta-blockers — atenolol, metoprolol, bisoprolol — cause fewer problems because they don’t significantly block beta-2 receptors. But selectivity isn’t absolute, and at high doses the line blurs.

Antidepressants: two different problems

Antidepressants concern dentistry for two distinct reasons, as Saraghi et al. (2017) explain.

Tricyclics (amitriptyline, nortriptyline, clomipramine) — they potentiate epinephrine’s effect. The mechanism: they block norepinephrine reuptake at sympathetic nerve endings, and the epinephrine injected with the anesthetic compounds a norepinephrine that lingers longer in the synaptic space. The result is an increased risk of arrhythmias and hypertension — especially if the vasoconstrictor dose is high or the injection is intravascular.

SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram) — the issue isn’t epinephrine but bleeding. Serotonin contributes to platelet aggregation. SSRIs reduce it. Wang et al. (2021), in their meta-analysis of 3.7 million warfarin patients, calculated an OR of 1.62 (95% CI 1.42–1.85) for clinically relevant bleeding when an SSRI is added to warfarin. Even without anticoagulants, SSRIs are an independent hemorrhagic risk factor — something the dentist accounts for when planning oral surgery.

NSAIDs: when the dentist prescribes to a patient already on medication

Dentists prescribe ibuprofen as if it were water. And most of the time it works — the ibuprofen + paracetamol combination is the gold standard for post-surgical pain. But the patient who already takes other drugs changes the picture.

NSAIDs + warfarin: Wang et al. (2021) report an OR of 1.83 (95% CI 1.29–2.59) for bleeding. NSAIDs inhibit platelet COX-1 and irritate the gastric mucosa — double risk in an already anticoagulated patient.

NSAIDs + low-dose aspirin: ibuprofen competes with aspirin for COX-1 binding. Taken before or simultaneously, it can reduce aspirin’s cardioprotective effect. Paracetamol doesn’t have this problem and is the natural alternative.

NSAIDs + antihypertensives (ACE inhibitors, ARBs, diuretics): NSAIDs blunt antihypertensive effect. In a patient taking ramipril or losartan, a week of ibuprofen can raise blood pressure by 5-10 mmHg. Not a disaster in a healthy person, but in a hypertensive patient already at the limit, it shifts the risk profile.

NSAIDs + SSRIs: the effect on bleeding risk is additive. Two drugs reducing platelet function through different pathways.

The practical rule: if the patient takes warfarin, DOACs, antiplatelets, SSRIs, or corticosteroids, paracetamol is nearly always the first-choice analgesic. Ibuprofen can be used, but knowing what’s on the other side.

Bisphosphonates and denosumab: the chapter that scares most

We covered this in a dedicated article on the 2025 consensus, and the message hasn’t changed: the risk of jaw osteonecrosis (MRONJ) in osteoporosis patients is 0.01–0.03%. Negligible. Don’t stop the drug before surgery — never without the endocrinologist’s advice, and especially never denosumab, which has a catastrophic rebound effect upon discontinuation.

What’s needed is a protocol: thorough pre-surgical hygiene, atraumatic technique, primary wound closure, antibiotics when indicated. Not fear.

Diabetes, metformin, and healing

Uncompensated diabetic patients heal poorly — that’s well known. But there’s a less known finding. Bastos et al. (2016) tested metformin on non-diabetic rats with titanium implants. Bone-to-implant contact (BIC) in the metformin group was significantly lower than controls, with increased RANKL expression — the signal that activates osteoclasts.

This is an animal model, and extrapolation to humans requires caution. But it suggests that metformin — the world’s most prescribed antidiabetic drug — may have a direct effect on osseointegration, independent of glycemic control.

GLP-1 agonists and semaglutide: the new drug in the chair

Ozempic, Wegovy, Mounjaro — patients on GLP-1 receptor agonists are multiplying. The implications for dentistry are still poorly studied. Two aspects deserve attention: delayed gastric emptying (aspiration risk under sedation) and the muscle mass loss that accompanies rapid weight reduction, with potential effects on bone metabolism.

The list that saves lives

Qadeer et al. (2019) analyzed the Lexicomp database — the reference for drug interactions in dentistry — and found that the most frequent drug-related complications during dental treatment boil down to three categories: interactions with local anesthetic, bleeding, and xerostomia. Three categories covering 90% of the problems.

Xerostomia deserves a mention: hundreds of drugs — antidepressants, antihypertensives, anticholinergics, diuretics, opioids — reduce salivary flow. Less saliva means less protection against decay, more candida infections, more prosthetic difficulties. The dentist sees it in the mouth before the patient talks about it.

Every time you sit in the dental chair, bring your medication list. Not “the important ones” — all of them. Because the dentist sees things that your GP might miss, and drug interactions are among them.

---

References

1. Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4051-4100. DOI: 10.1111/bcp.14833
2. Johansson K, Becktor JP, Naimi-Akbar A, et al. Continuous use of direct oral anticoagulants during and after simple and surgical tooth extractions. BMC Oral Health. 2025;25(1):554. DOI: 10.1186/s12903-025-05949-9
3. Hua W, Huang Z, Huang Z. Bleeding outcomes after dental extraction in patients under DOACs vs. VKAs: a systematic review and meta-analysis. Front Pharmacol. 2021;12:702057. DOI: 10.3389/fphar.2021.702057
4. Ono S, Ishimaru M, Yokota I, et al. Risk of post-extraction bleeding with DOACs vs. warfarin: retrospective cohort study. Thromb Res. 2022;222:24-30. DOI: 10.1016/j.thromres.2022.12.007
5. Lu SY, Lin LH, Hsue SS. Management of dental extractions in patients on warfarin and antiplatelet therapy. J Formos Med Assoc. 2018;117(11):979-986. DOI: 10.1016/j.jfma.2018.08.019
6. Hersh EV, Giannakopoulos H. Beta-adrenergic blocking agents and dental vasoconstrictors. Dent Clin North Am. 2010;54(4):687-696. DOI: 10.1016/j.cden.2010.06.009
7. Saraghi M, Golden LR, Hersh EV. Anesthetic considerations for patients on antidepressant therapy — Part I. Anesth Prog. 2017;64(4):253-261. DOI: 10.2344/anpr-64-04-14
8. Schreuder WH, Peacock ZS. Antiplatelet therapy and exodontia. J Am Dent Assoc. 2015;146(11):851-856. DOI: 10.1016/j.adaj.2015.04.024
9. Dinkova AS, Atanasov DT, Vladimirova-Kitova LG. Discontinuation of oral antiplatelet agents before dental extraction — necessity or myth? Folia Med (Plovdiv). 2017;59(3):336-343. DOI: 10.1515/folmed-2017-0043
10. Bastos MF, Serrão CR, Miranda TS, et al. Effects of metformin on bone healing around titanium implants in non-diabetic rats. Clin Oral Implants Res. 2016;28(10):e146-e150. DOI: 10.1111/clr.12960
11. Qadeer A, Omolehinwa TT, Mupparapu M, Akintoye SO. Are drug-related dental management cautions in Lexicomp evidence-based? Quintessence Int. 2019;50(9):754-761. DOI: 10.3290/j.qi.a43090